give an educated guess to this quarters numbers. I believe we have 14M Nipent revenue and 5M cilag. We should have the first royality on Dacogen shipment in June (approx. 1M royality). They had revenue of 24M and profit of 4.3M last quarter. They also paid out 9M for Montigen pipeline and 2.1M for Nipent transfer rights. I do not see these large charges this quarter. For the bashers I understand that most of this revenue is one time fees. Just trying to get a handle on what will be reported. I expect SUPG to give a little better insight into next quarters revenue and expense side.
SG&A will also drop by 55% going forward, but we will see SG&A drop by $1M this Q, and $3 M going forward. Also R&D will drop by 10%. Dacogen Revenue will be $1.0M this reported Q, remember we are a Q behind on this. So I have revenue for the 3rd Q @ $13.1M (Nipent) + $5M J&J, net sales of $2.5M Nipent , $1.0 for Dacogen, $500k of interest income and expenses of SG&A $5M andd R&D of $3M = net income of $13.6 M or $0.25 a share.